Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma

• DOI: 10.1126/scitranslmed.aad9784
• Publication Date: 2016-06-02T01:19:13Z
• Authors: Timothy F. Cloughesy; Joseph Landolfi; Daniel J. Hogan; Stephen Bloomfield; Bob Carter; Clark C. Chen; J. Bradley Elder; Steven N. Kalkanis; Santosh Kesari; Albert Lai; Ian Y. Lee; Linda M. Liau; Tom Mikkelsen; Phioanh Leia Nghi...; David Piccioni; Tobias Walbert; Alice Chu; Asha Das; Oscar R. Diago; Dawn Gammon; Harry E. Gruber; Michelle Hanna; Douglas J. Jolly; Noriyuki Kasahara; David McCarthy; Leah Mitchell; Derek Ostertag; Joan M. Robbins; Maria Rodriguez-A...; Michael A. Vogelbaum
• Keywords: Clinical Sciences; Oncology and Carcinogenesis; Clinical Trials and Supportive Activities; Messenger; Genetic Vectors; Medical biotechnology; Flucytosine; Medical and Health Sciences; Cytosine Deaminase; Rare Diseases; Clinical Research; Genetics; Confidence Intervals; Prodrugs; RNA, Messenger; Cancer; Biomedical and Clinical Sciences; Glioma; Biological Sciences; Brain Disorders; 3. Good health; Brain Cancer; Retroviridae; 6.1 Pharmaceuticals; RNA; Fluorouracil; Biomedical engineering

Toca 511 and Toca FC show promising results in treating recurrent high-grade glioma, and a specific molecular signature correlates with treatment-related survival.